A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and ch...
- Autores:
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13430
- Acceso en línea:
- https://www.nature.com/articles/s41467-020-18058-8
http://hdl.handle.net/20.500.12010/13430
https://doi.org/10.1038/s41467-020-18058-8
- Palabra clave:
- SARS-CoV-2
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)